메뉴 건너뛰기




Volumn 78, Issue 12, 2019, Pages 1609-1615

Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis

Author keywords

DAS28; dmards (synthetic); rheumatoid arthritis; TNF alpha

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT;

EID: 85071141082     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2018-214918     Document Type: Article
Times cited : (41)

References (29)
  • 1
    • 84932633475 scopus 로고    scopus 로고
    • Association of socioeconomic status with treatment delays, disease activity, joint damage, and disability in rheumatoid arthritis
    • Molina E, Del Rincon I, Restrepo JF, et al. Association of socioeconomic status with treatment delays, disease activity, joint damage, and disability in rheumatoid arthritis. Arthritis Care Res 2015;67:940-6.
    • (2015) Arthritis Care Res , vol.67 , pp. 940-946
    • Molina, E.1    Del Rincon, I.2    Restrepo, J.F.3
  • 2
    • 0029869174 scopus 로고    scopus 로고
    • The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial
    • van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
    • (1996) Ann Intern Med , vol.124 , pp. 699-707
    • Van Der Heide, A.1    Jacobs, J.W.2    Bijlsma, J.W.3
  • 3
    • 0035886157 scopus 로고    scopus 로고
    • Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: Comparison of two cohorts who received different treatment strategies
    • Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
    • (2001) Am J Med , vol.111 , pp. 446-451
    • Lard, L.R.1    Visser, H.2    Speyer, I.3
  • 4
    • 84877634558 scopus 로고    scopus 로고
    • Very early rheumatoid arthritis as a predictor of remission: A multicentre real life prospective study
    • Gremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis 2013;72:858-62.
    • (2013) Ann Rheum Dis , vol.72 , pp. 858-862
    • Gremese, E.1    Salaffi, F.2    Bosello, S.L.3
  • 5
    • 3242886819 scopus 로고    scopus 로고
    • Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis
    • Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906-14.
    • (2004) Rheumatology , vol.43 , pp. 906-914
    • Nell, V.P.1    Machold, K.P.2    Eberl, G.3
  • 6
    • 84860920048 scopus 로고    scopus 로고
    • Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): Post hoc analyses from the COMET study
    • Emery P, Kvien TK, Combe B, et al. Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis 2012;71:989-92.
    • (2012) Ann Rheum Dis , vol.71 , pp. 989-992
    • Emery, P.1    Kvien, T.K.2    Combe, B.3
  • 7
    • 84877602545 scopus 로고    scopus 로고
    • Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study
    • Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844-50.
    • (2013) Ann Rheum Dis , vol.72 , pp. 844-850
    • Detert, J.1    Bastian, H.2    Listing, J.3
  • 8
    • 31044442965 scopus 로고    scopus 로고
    • The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
    • Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
    • (2006) Arthritis Rheum , vol.54 , pp. 26-37
    • Breedveld, F.C.1    Weisman, M.H.2    Kavanaugh, A.F.3
  • 9
    • 85037610933 scopus 로고    scopus 로고
    • Effect of disease duration on clinical outcomes in moderate rheumatoid arthritis patients treated with etanercept plus methotrexate in the Preserve study
    • Smolen J, Collier D, Szumski A, et al. Effect of disease duration on clinical outcomes in moderate rheumatoid arthritis patients treated with etanercept plus methotrexate in the Preserve study. Arthritis Rheumatol 2014;66.
    • (2014) Arthritis Rheumatol , vol.66
    • Smolen, J.1    Collier, D.2    Szumski, A.3
  • 10
    • 2342658406 scopus 로고    scopus 로고
    • Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial
    • Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
    • (2004) Arthritis Rheum , vol.50 , pp. 1400-1411
    • Keystone, E.C.1    Kavanaugh, A.F.2    Sharp, J.T.3
  • 12
    • 0034082253 scopus 로고    scopus 로고
    • Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration
    • Anderson JJ, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
    • (2000) Arthritis Rheum , vol.43 , pp. 22-29
    • Anderson, J.J.1    Wells, G.2    Verhoeven, A.C.3
  • 13
    • 85069006546 scopus 로고    scopus 로고
    • Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis
    • Soriano ER, Dellepiane A, Salvatierra G, et al. Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis. Future Sci OA 2018;4.
    • (2018) Future Sci OA , vol.4
    • Soriano, E.R.1    Dellepiane, A.2    Salvatierra, G.3
  • 14
    • 84929028357 scopus 로고    scopus 로고
    • FRI0160 efficacy of abatacept in RA patients with an inadequate response to anti-TNF therapy regardless of reason for failure, or type or number of prior anti-TNF therapy used
    • Schiff M, Zhou X, Kelly S, et al. FRI0160 efficacy of abatacept in RA patients with an inadequate response to anti-TNF therapy regardless of reason for failure, or type or number of prior anti-TNF therapy used. Ann Rheum Dis 2008;67(Suppl 2).
    • (2008) Ann Rheum Dis , vol.67
    • Schiff, M.1    Zhou, X.2    Kelly, S.3
  • 15
    • 0037231533 scopus 로고    scopus 로고
    • Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
    • Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
    • (2003) Arthritis Rheum , vol.48 , pp. 35-45
    • Weinblatt, M.E.1    Keystone, E.C.2    Furst, D.E.3
  • 16
    • 31144454164 scopus 로고    scopus 로고
    • Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials
    • Aletaha D, Ward MM. Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis 2006;65:227-33.
    • (2006) Ann Rheum Dis , vol.65 , pp. 227-233
    • Aletaha, D.1    Ward, M.M.2
  • 17
    • 38749129727 scopus 로고    scopus 로고
    • Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: A pooled analysis of clinical trial results
    • Aletaha D, Strand V, Smolen JS, et al. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008;67:238-43.
    • (2008) Ann Rheum Dis , vol.67 , pp. 238-243
    • Aletaha, D.1    Strand, V.2    Smolen, J.S.3
  • 18
    • 79958840089 scopus 로고    scopus 로고
    • Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry
    • Furst DE, Pangan AL, Harrold LR, et al. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res 2011;63:856-64.
    • (2011) Arthritis Care Res , vol.63 , pp. 856-864
    • Furst, D.E.1    Pangan, A.L.2    Harrold, L.R.3
  • 19
    • 84896861959 scopus 로고    scopus 로고
    • The effect of socioeconomic class and immigrant status on disease activity in rheumatoid arthritis: Data from BARFOT, a multi-centre study of early RA
    • Andersson ML, Bergman S, Söderlin MK. The effect of socioeconomic class and immigrant status on disease activity in rheumatoid arthritis: data from BARFOT, a multi-centre study of early RA. Open Rheumatol J 2013;7:105-11.
    • (2013) Open Rheumatol J , vol.7 , pp. 105-111
    • Andersson, M.L.1    Bergman, S.2    Söderlin, M.K.3
  • 20
    • 84959552894 scopus 로고    scopus 로고
    • Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice
    • Narváez J, Magallares B, Díaz Torné C, et al. Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. Semin Arthritis Rheum 2016;45:386-90.
    • (2016) Semin Arthritis Rheum , vol.45 , pp. 386-390
    • Narváez, J.1    Magallares, B.2    Díaz Torné, C.3
  • 21
    • 84946606033 scopus 로고    scopus 로고
    • RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEG (PEGol) rheumatoid arthritis-treated patients from a Spanish multicenter national database
    • Torrente-Segarra V, Urruticoechea Arana A, Sánchez-Andrade Fernández A, et al. RENACER study: assessment of 12-month efficacy and safety of 168 certolizumab PEG (PEGol) rheumatoid arthritis-treated patients from a Spanish multicenter national database. Mod Rheumatol 2016;26:336-41.
    • (2016) Mod Rheumatol , vol.26 , pp. 336-341
    • Torrente-Segarra, V.1    Urruticoechea Arana, A.2    Sánchez-Andrade Fernández, A.3
  • 22
    • 84926434271 scopus 로고    scopus 로고
    • Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: Does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts
    • van Nies JAB, Tsonaka R, Gaujoux-Viala C, et al. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis 2015;74:806-12.
    • (2015) Ann Rheum Dis , vol.74 , pp. 806-812
    • Van Nies, J.A.B.1    Tsonaka, R.2    Gaujoux-Viala, C.3
  • 23
    • 0037216311 scopus 로고    scopus 로고
    • Contribution of patient related differences to multidrug resistance in rheumatoid arthritis
    • Morgan C, Lunt M, Brightwell H, et al. Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Ann Rheum Dis 2003;62:15-19.
    • (2003) Ann Rheum Dis , vol.62 , pp. 15-19
    • Morgan, C.1    Lunt, M.2    Brightwell, H.3
  • 24
    • 84871033136 scopus 로고    scopus 로고
    • Forget personalised medicine and focus on abating disease activity
    • Smolen JS, Aletaha D. Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis 2013;72:3-6.
    • (2013) Ann Rheum Dis , vol.72 , pp. 3-6
    • Smolen, J.S.1    Aletaha, D.2
  • 25
    • 27744514865 scopus 로고    scopus 로고
    • Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial
    • Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
    • (2005) Arthritis Rheum , vol.52 , pp. 3381-3390
    • Goekoop-Ruiterman, Y.P.M.1    De Vries-Bouwstra, J.K.2    Allaart, C.F.3
  • 26
    • 85019702082 scopus 로고    scopus 로고
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
    • Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
    • (2017) Ann Rheum Dis , vol.76 , pp. 960-977
    • Smolen, J.S.1    Landewé, R.2    Bijlsma, J.3
  • 27
    • 79955156664 scopus 로고    scopus 로고
    • Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity-The early RA network (ERAN)
    • Kiely P, Walsh D, Williams R, et al. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity-the early RA network (ERAN). Rheumatology 2011;50:926-31.
    • (2011) Rheumatology , vol.50 , pp. 926-931
    • Kiely, P.1    Walsh, D.2    Williams, R.3
  • 28
    • 84940744778 scopus 로고    scopus 로고
    • APLAR rheumatoid arthritis treatment recommendations
    • Lau CS, Chia F, Harrison A, et al. APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis 2015;18:685-713.
    • (2015) Int J Rheum Dis , vol.18 , pp. 685-713
    • Lau, C.S.1    Chia, F.2    Harrison, A.3
  • 29
    • 85003681006 scopus 로고    scopus 로고
    • Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
    • Smolen JS, Burmester G-R, Combe B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 2016;388:2763-74.
    • (2016) Lancet , vol.388 , pp. 2763-2774
    • Smolen, J.S.1    Burmester, G.-R.2    Combe, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.